📰 Human Insulin News
Human Insulin News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Human Insulin. Real-time updates on events, politics, business and more.
January 11, 2024
The Human Insulin market, forecasted from 2023 to 2030, encompasses two primary insulin types:
November 3, 2023
Human Insulin Market to Surpass USD 20.99 Billion by 2030 on Account of Rising Diabetes Prevalence and Rapid Healthcare Infrastructure Development
September 20, 2023
Danish pharmaceutical company Novo Nordisk signed a deal with South Africa's Aspen Pharmacare to produce human insulin for diabetes patients in Africa, where there is a dire need for the life-saving treatment. The Africa Centers for Disease Control and Prevention welcomed the move Wednesday, saying it would “greatly impact the fight against diabetes” in Africa.
August 9, 2023
Dublin, Aug. 09, 2023 (GLOBE NEWSWIRE) -- The "Global Insulin Pen Market, Users, Global Forecast 2023-2028, Industry Trends, Share, Growth, Insight,...
July 28, 2023
/PRNewswire/ -- The "Global Insulin Pen Market, Users, Global Forecast 2023-2028, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company...
April 28, 2023
In its latest report, Data Bridge Market Research dissects growth strategies, drivers, opportunities, key segments, Porters Five Forces analysis, and the
January 13, 2023
Burlingame, Jan. 12, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, Global Human Insulin Drug Market is estimated to be valued at US$...
January 12, 2023
Human Insulin Market Size By Type (Traditional Human Insulin and Modern Human Insulin), By Distribution Channel (Hospitals, Retail Pharmacies, And Others),...
December 30, 2022
According to estimates, the global market for Human Insulin was worth US$ 22.3 billion in 2021, growing at a CAGR of 3.2% through 2032.This sort of synthetic insulin created at research labs is generally a recombinant human insulin product.It is created biologically by engineering insulin proteins within Escherichia...
November 23, 2022
Cost is a huge barrier to insulin access in LMICs. Human insulins are still out of the reach of many people with diabetes. When available, analogues are very expensive and can cost two to six times more than human insulins. There are also wide variations in price across countries